EpilepsyGTX Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$32.6M
- Investors
-
10
EpilepsyGTX General Information
Description
Developer of gene therapies designed for neurological disorder treatment. The company's platform utilizes genetic engineering techniques to modify cells, delivering therapeutic genes to targeted areas within the brain, often involving viral vectors and specialized delivery systems, enabling researchers and clinicians to explore potential treatments for epilepsy.
Contact Information
Website
focalisbio.comCorporate Office
- Camburgh House
- 27 New Dover Road, Kent
- Canterbury CT1 3DN
- England, United Kingdom
Corporate Office
- Camburgh House
- 27 New Dover Road, Kent
- Canterbury CT1 3DN
- England, United Kingdom
EpilepsyGTX Timeline
EpilepsyGTX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 11-Dec-2025 | $32.6M | Completed | Generating Revenue | ||
| 4. Seed Round | 24-Jun-2024 | Completed | Generating Revenue | |||
| 3. Seed Round | 01-Dec-2023 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2023 | $851K | Completed | Generating Revenue | ||
| 1. University Spin-Out | 24-May-2021 | Completed | Generating Revenue |
EpilepsyGTX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed | 4,000,000 | $0.000013 | $1.32 | $1.32 | 1x | $1.32 | 21.68% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
EpilepsyGTX Signals
EpilepsyGTX Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| XGEN Venture | Impact Investing | Minority | ||
| AlbionVC | Venture Capital | Minority | ||
| Health Technology Holding | Venture Capital | Minority | ||
| UCL Ventures | University | Minority |
EpilepsyGTX FAQs
-
When was EpilepsyGTX founded?
EpilepsyGTX was founded in 2021.
-
Where is EpilepsyGTX headquartered?
EpilepsyGTX is headquartered in Canterbury, United Kingdom.
-
What is the size of EpilepsyGTX?
EpilepsyGTX has 2 total employees.
-
What industry is EpilepsyGTX in?
EpilepsyGTX’s primary industry is Therapeutic Devices.
-
Is EpilepsyGTX a private or public company?
EpilepsyGTX is a Private company.
-
What is the current valuation of EpilepsyGTX?
The current valuation of EpilepsyGTX is .
-
What is EpilepsyGTX’s current revenue?
The current revenue for EpilepsyGTX is .
-
How much funding has EpilepsyGTX raised over time?
EpilepsyGTX has raised $47.5M.
-
Who are EpilepsyGTX’s investors?
British Business Bank, XGEN Venture, AlbionVC, Health Technology Holding, and UCL Ventures are 5 of 10 investors who have invested in EpilepsyGTX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process